Access to large genetic data sets, many of which are privately owned, is essential to precision medicine and other research protocols. Academic researchers are increasingly capitalizing on this privately held data. Our goal is to understand these private–academic “genetic data partnerships.”
We analyzed publications using human genetic data generated or held by major private genetic testing companies that were indexed in PubMed between 2011 and 2017.
We found that (1) the number of publications using private genetic data is increasing over time (from 4 in 2011 to 57 in 2017); (2) there are two main models of data-sharing, including researchers using existing private data held by industry (n = 172) or researchers sending in new samples for analysis (n = 6); (3) 45% of the publications were supported at least in part by the National Institutes of Health; and (4) the type of contributor consent is not disclosed/unclear in the publication almost half (43%) the time.
Privately held or analyzed genetic databanks offer academic researchers the opportunity to efficiently access large amounts of genetic data. But more transparency should be encouraged, if not required, to ensure the proper notification of contributors and to further understand the use of public research funds for private collaborations.
Subscribe to Journal
Get full journal access for 1 year
only $94.83 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
US Department of Health and Human Services. All of Us Research Program. https://allofus.nih.gov/. Accessed 26 April 2019.
Wilbanks JT, Topol EJ. Stop the privatization of health data. Nature. 2016;535:345–348.
Research and Markets. Global consumer DNA (genetic) testing market—forecasts from 2018–2023. https://www.researchandmarkets.com/research/w4fsmm/global_928?w=5. Accessed 26 April 2019.
23andMe. 23andMe for healthcare professionals. https://medical.23andme.com/. Accessed 26 April 2019.
GSK. GSK and 23andMe sign agreement to leverage genetic insights for the development of novel medicines. https://www.gsk.com/en-gb/media/press-releases/gsk-and-23andme-sign-agreement-to-leverage-genetic-insights-for-the-development-of-novel-medicines/. Accessed 26 April 2019.
Lehmann LS, et al. Navigating a research partnership between academia and industry to assess the impact of personalized genetic testing. Genet Med. 2012;14:268–273.
Spector-Bagdady K, et al. Encouraging participation and transparency in biobank research. Health Aff (Millwood). 2018;37:1313–1320.
Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015;372:793–795.
This work was funded by the National Center for Advancing Translational Sciences (UL1TR002240) and the National Human Genome Research Institute (K01HG010496).
The full list of articles included in this literature review is available from the corresponding author upon request.
The authors declare no conflicts of interest.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Spector-Bagdady, K., Fakih, A., Krenz, C. et al. Genetic data partnerships: academic publications with privately owned or generated genetic data. Genet Med 21, 2827–2829 (2019). https://doi.org/10.1038/s41436-019-0569-z
- precision medicine
- private companies
- academic researchers